Researchers, led by an infectious disease expert at the University of California, Riverside, report the identification of two proteins that are key to Plasmodium falciparum’s survival. The discovery and related paper “Functional genomics of RAP proteins and their role in mitoribosome regulation in Plasmodium falciparum”, published in Nature Communications, suggests these proteins—RAP01 and RAP21—could be potential targets for novel antimalarial and antiparasitic strategies.
“The RAP (RNA-binding domain abundant in Apicomplexans) protein family has been identified in various organisms. Despite expansion of this protein family in apicomplexan parasites, their main biological functions remain unknown. In this study, we use inducible knockdown studies in the human malaria parasite, Plasmodium falciparum, to show that two RAP proteins, PF3D7_0105200 (PfRAP01) and PF3D7_1470600 (PfRAP21), are essential for parasite survival and localize to the mitochondrion.
“Using transcriptomics, metabolomics, and proteomics profiling experiments, we further demonstrate that these RAP proteins are involved in mitochondrial RNA metabolism. Using high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation (eCLIP-seq), we validate that PfRAP01 and PfRAP21 are true RNA-binding proteins and interact specifically with mitochondrial rRNAs.
Finally, mitochondrial enrichment experiments followed by deep sequencing of small RNAs demonstrate that PfRAP21 controls mitochondrial rRNA expression.
“Collectively, our results establish the role of these RAP proteins in mitoribosome activity and contribute to further understanding this protein family in malaria parasites.”
“Understanding the exact function of this pair of proteins could lead to the discovery of new therapeutic strategies to fight malaria,” said Karine Le Roch, a professor of molecular, cell, and systems biology. “Using advanced genome editing technology, we were able to show that these two proteins are intimately linked to P. falciparum’s mitochondria, the cells’ powerhouses. Without these proteins, the mitochondria cannot ensure the parasite’s function and it dies.”
The pair of proteins belong to the “RNA-binding domain abundant in Apicomplexans,” or RAP, protein family, which has been identified in several organisms. Their main biological function has eluded scientists. Despite their potential as novel therapeutic targets, they remain poorly characterized.
Le Roch explained that human cells have only a small number of RAP proteins. But Apicomplexan parasites—such as P. falciparum and the toxoplasmosis-causing microbe Toxoplasma gondii—have a large number of these proteins. Further, the mitochondria in Apicomplexan parasites differ greatly from those in humans. For example, Apicomplexan parasites have many fragmented ribosomal RNAs in their mitochondria. Human mitochondria, on the other hand, have long, unfragmented ribosomal RNAs.
“RAP01 and RAP21 may be instrumental in bringing all the fragmented ribosomal RNAs together,” said Le Roch, who directs the UCR Center for Infectious Disease and Vector Research. “These RNAs are essential for protein translation in the mitochondria. If drugs can be developed to knock down RAP01 and RAP21, the whole process would be interrupted, leading to the parasite’s death. Such drugs are unlikely to affect human mitochondria because they differ vastly from mitochondria of Apicomplexan parasites.”
According to Le Roch, RAP01 and RAP21 are detected and expressed at higher levels at every stage of the Apicomplexan parasite lifecycle. Her team used the CRISPR-Cas9 genome-editing tool to knock down these proteins. When death of the Apicomplexan parasite followed, the team realized the proteins were essential to the parasite’s survival.
Le Roch’s team was joined by researchers from MIT and the Stowers Institute for Medical Research in Missouri.